Showing posts with label diazepam. Show all posts
Showing posts with label diazepam. Show all posts

Wednesday, February 3, 2016

Comparison of Drugs Used by Nightclub Patrons & Criminal Offenders in Oslo, Norway

The aim of this study was to investigate psychoactive drug use among nightclub patrons by analysing samples of oral fluid and compare with findings in blood samples from criminal suspects. 

We hypothesized that the profile of illicit drug use among nightclub patrons is different from what we observe in those forensic cases. Research stations were established outside nine popular nightclubs with different profiles and patron-characteristics in downtown Oslo. Data and sample collection was conducted on Fridays and Saturdays in March and May 2014. Individuals and groups who entered defined recruitment zones from 23:00 to 03:30 were invited to participate in this voluntary and anonymous study. Oral fluid was collected using the Intercept Oral Fluid Sampling Device. Methanol was added to increase the recovery of cannabinoids from the device. Sample preparation was performed using liquid-liquid extraction with ethyl acetate/heptane (4:1) after adding internal standards, ammonium carbonate buffer pH 9.3 and Triton X100. The first 80 samples were analysed for 122 substances, which included psychoactive medicinal drugs, classical illicit drugs and new psychoactive substances (NPS). Based on the findings and discussions with police and customs authorities, the remaining oral fluid samples were analysed for 46 substances. 

Among the 500 samples collected during the study period, we found illicit drugs in 25.4% and medicinal drugs in 4.2% of the samples. The most prevalent substances were: cocaine 14.6%, THC 12.4%, amphetamine/methamphetamine 2.8%, diazepam 1.2% and clonazepam 1.0%. Various NPS were found in 1.4% of the samples. 

The prevalence of drugs in blood samples from criminal suspects were for cocaine 3.4%, THC 34.7%, amphetamine/methamphetamine 37.0%, diazepam 12.0%, and clonazepam 29.3%. Multi-drug use was more common among criminal suspects (41.3%) than among club patrons (6.8%). 

The results showed that the drug use pattern among nightclub patrons was substantially different from the drug use pattern manifested by individuals apprehended by the police suspected for criminal conduct.

Purchase full article at:   http://goo.gl/E3DlOl

  • 1Division of Forensic Sciences, Norwegian Institute of Public Health, PO Box 4404, Nydalen, NO-0403 Oslo, Norway. Electronic address: hallvard.gjerde@fhi.no.
  • 2Norwegian Institute for Alcohol and Drug Research (SIRUS), PO Box 565, Sentrum, NO-0105 Oslo, Norway.
  • 3Division of Forensic Sciences, Norwegian Institute of Public Health, PO Box 4404, Nydalen, NO-0403 Oslo, Norway. 
  •  2015 Dec 30;265:1-5. doi: 10.1016/j.forsciint.2015.12.029




Friday, January 29, 2016

Attitudes Towards a Maintenance (-agonist) Treatment Approach in High-Dose Benzodiazepine-Dependent Patients

BACKGROUND:
High-dose benzodiazepine dependence constitutes a major clinical concern. Although withdrawal treatment is recommended, it is unsuccessful for a significant proportion of affected patients. More recently, a benzodiazepine maintenance approach has been suggested as an alternative for patients' failing discontinuation treatment. While there is some data supporting its effectiveness, patients' perceptions of such an intervention have not been investigated.

METHODS:
An exploratory qualitative study was conducted among a sample of 41 high-dose benzodiazepine (BZD)-dependent patients, with long-term use defined as doses equivalent to more than 40 mg diazepam per day and/or otherwise problematic use, such as mixing substances, dose escalation, recreational use, or obtainment by illegal means. A qualitative content analysis approach was used to evaluate findings.

RESULTS:
Participants generally favored a treatment discontinuation approach with abstinence from BZD as its ultimate aim, despite repeated failed attempts at withdrawal. A maintenance treatment approach with continued prescription of a slow-onset, long-acting agonist was viewed ambivalently, with responses ranging from positive and welcoming to rejection. Three overlapping themes of maintenance treatment were identified: "Only if I can try to discontinue…and please don't call it that," "More stability and less criminal activity…and that is why I would try it," and "No cure, no brain and no flash…and thus, just for everybody else!"

CONCLUSIONS:
Some patients experienced slow-onset, long-acting BZDs as having stabilized their symptoms and viewed these BZDs as having helped avoid uncontrolled withdrawal and abstain from criminal activity. We therefore encourage clinicians to consider treatment alternatives if discontinuation strategies fail.

...In this explorative study, participants often used the term “substitution” in their initial narrative, primarily while referring to the substitution of benzodiazepines for other psychotropic substances like alcohol or heroin. The statement of VP22 exemplifies this perception:

“…Initially I took mostly heroin and when I wanted to sleep I just waited until the flash wore off. But when I could not fall asleep this way, then I thought, instead of taking more Heroin, I take a benzodiazepine, then I did not just save money, but it also helped better to fall asleep. O.k. with heroin you can also fall asleep, but actually out of cost considerations I switched over to benzodiazepines...”
VP 22, male, 46 years

Furthermore, participants associated “substitution” with the replacement of BZDs with a non-BZD class of agents such as antipsychotics or antidepressants, which was something they had often experienced during treatment. In addition, some participants described a long-term BZD maintenance approach with a slow-onset, long-acting BZD, when referring to previous experiences and preferences for different kinds of BZDs. Only few participants had heard of a “maintenance” approach by their treating physicians, reflecting the heterogeneity of this sample in regard to treatment duration (weeks to years) and form of intervention, ranging from abstinence-oriented benzodiazepine discontinuation approach to the more permanent prescription of slow-onset, long-acting BZDs.

Perceptions and beliefs about an agonist treatment (or “maintenance”) approach had to be elucidated using non-judgmental questions: “How would you feel about a substitution for benzodiazepines? Like, for example, heroin, that gets substituted with methadone?” Furthermore and in cases of highly knowledgeable participants, we gave more specific examples for slow-onset, long-acting benzodiazepines usually by mentioning specific brand names.

However, participants’ statements in regard to such a treatment strategy sometimes appeared to contradict their previous statements or explanations. Although we tried to clarify apparent inconsistencies using additional probes, they persisted in four instances:

“…For me, personally, that is nothing…I think that is a stupid question, but with heroin you have, but I never tried heroin, as far as I know you have a “high.” And that is something you don’t have with methadone. The “high” feeling is removed with methadone—it just eases withdrawal effects…And benzodiazepines do not make a “high,” so there is no “high” feeling, at least not with me…so I would not take (substituting drugs) since I don’t have side effects from benzodiazepines…if someone just overcomes feelings of anxiety and then does not need benzos anymore, then I think it is good, if there is such a development…but I am very happy that they are around...”
VP6, male, 30 years... 

Full article at:   http://goo.gl/NhY0yN

  • 1Department of Forensic Psychiatry, Institute of Legal Medicine, University of Bern, Bern, Switzerland. Michael.Liebrenz@fpd.unibe.ch.
  • 2Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland. Michael.Liebrenz@fpd.unibe.ch.
  • 3Department of Surgery, Division of Visceral and Transplantation Surgery, University Hospital Zurich, Zurich, Switzerland. marcelandre.schneider@gmail.com.
  • 4Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland. Anna.Buadze@puk.zh.ch.
  • 5Ulmenhof, Sozialtherapie, Ottenbach, Switzerland. marie-therese.gehring@diealternative.ch.
  • 6University of Pennsylvania Health System, Philadelphia, USA. Anish.Dube@gmail.com.
  • 7Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland. Carlo.Caflisch@puk.zh.ch. 
  •  2016 Jan 8;13(1):1. doi: 10.1186/s12954-015-0090-x.




Wednesday, September 23, 2015

Prevalence & Correlates of HCV Monoinfection & HIV & HCV Coinfection among Persons Who Inject Drugs in Vietnam

Vietnam bears a high burden of hepatitis C virus (HCV) and HIV infection among persons who inject drugs (PWID). The high prevalence of HCV and HIV occurs in a context of stigma and limited preventive interventions for PWID.

This study aims to estimate the prevalence of HCV, HIV, and HIV/HCV coinfection among PWID and to explore their associations with lifetime injection behaviors.

A total of 1434 PWID were recruited from the Thai Nguyen Province of Vietnam between 2005 and 2007. Participants responded to a structured questionnaire and provided blood samples at baseline. A cross-sectional analysis of data collected at baseline was carried out. Factors associated with HCV monoinfection and HIV/HCV coinfection were evaluated by multinomial logistic regression.

The prevalences of HIV and HCV were 35.1 and 88.8%, respectively, and the prevalences of HIV/HCV coinfection and HCV monoinfection were 34.8 and 53.9%, respectively. After adjusting for confounders in multivariate analysis, ever reusing a syringe and needle was found to be significantly associated with HIV monoinfection and HIV/HCV coinfection. Ever sharing diazepam or novocaine was also found to be significantly associated with HIV monoinfection and HIV/HCV coinfection.

Our findings demonstrate a high burden of HIV and HCV infection among PWID in Vietnam. Lifetime injection behaviors, including sharing of diazepam or novocaine, may account for the high prevalence of HIV and HCV. Improving prevention and ensuring access to care remain critically important for this vulnerable population.

Via:  http://ht.ly/SASgJ Purchase full article at: http://goo.gl/6UrXVl

  • 1Departments of aEpidemiology bHealth, Behavior and Society cBiostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland dDepartment of Health Behavior, UNC Gillings School of Global Public Health, Chapel Hill, North Carolina, USA eThai Nguyen Center for Preventive Medicine, Thai Nguyen, Vietnam.